iTeos Therapeutics (NASDAQ:ITOS) Receives “Outperform” Rating from Wedbush

Wedbush restated their outperform rating on shares of iTeos Therapeutics (NASDAQ:ITOS) in a research report released on Tuesday morning,RTT News reports. The firm currently has a $25.00 price objective on the stock. Wedbush also issued estimates for iTeos Therapeutics’ Q4 2024 earnings at ($0.95) EPS, FY2024 earnings at ($3.26) EPS, Q1 2025 earnings at ($1.01) EPS, Q2 2025 earnings at ($1.13) EPS, Q3 2025 earnings at ($1.19) EPS, Q4 2025 earnings at ($1.23) EPS, FY2025 earnings at ($4.56) EPS, FY2026 earnings at ($5.26) EPS, FY2027 earnings at ($4.54) EPS and FY2028 earnings at ($1.26) EPS.

A number of other research firms have also recently commented on ITOS. HC Wainwright reiterated a “buy” rating and set a $46.00 price target on shares of iTeos Therapeutics in a report on Monday, September 16th. JPMorgan Chase & Co. lowered their price objective on shares of iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. Finally, Wells Fargo & Company started coverage on shares of iTeos Therapeutics in a research report on Tuesday, August 13th. They set an “overweight” rating and a $31.00 price objective on the stock.

iTeos Therapeutics Stock Performance

Shares of NASDAQ:ITOS traded down $0.26 during trading on Tuesday, reaching $8.20. 76,249 shares of the stock traded hands, compared to its average volume of 438,585. The stock has a 50-day moving average of $10.40 and a two-hundred day moving average of $13.99. iTeos Therapeutics has a 52-week low of $8.05 and a 52-week high of $18.75. The stock has a market cap of $299.55 million, a P/E ratio of -2.69 and a beta of 1.39.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ITOS. nVerses Capital LLC boosted its stake in shares of iTeos Therapeutics by 212.5% during the 3rd quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock worth $26,000 after acquiring an additional 1,700 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of iTeos Therapeutics by 60.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock worth $72,000 after acquiring an additional 2,646 shares during the last quarter. Quest Partners LLC boosted its stake in shares of iTeos Therapeutics by 914.7% during the 3rd quarter. Quest Partners LLC now owns 11,020 shares of the company’s stock worth $113,000 after acquiring an additional 9,934 shares during the last quarter. US Bancorp DE boosted its stake in shares of iTeos Therapeutics by 206.0% during the 3rd quarter. US Bancorp DE now owns 12,076 shares of the company’s stock worth $123,000 after acquiring an additional 8,129 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in shares of iTeos Therapeutics during the 3rd quarter worth $126,000. Hedge funds and other institutional investors own 97.16% of the company’s stock.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.